Filing Details
- Accession Number:
- 0001437749-21-021016
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-08-25 20:03:40
- Reporting Period:
- 2021-08-23
- Accepted Time:
- 2021-08-25 20:03:40
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
834365 | Biolife Solutions Inc | BLFS | Electromedical & Electrotherapeutic Apparatus (3845) | 943076866 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1683151 | A. Karen Foster | C/O Biolife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310 Bothell WA 98021 | Chief Quality Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-08-23 | 16,332 | $1.64 | 89,109 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-08-23 | 16,332 | $46.54 | 72,777 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-08-23 | 16,332 | $0.00 | 16,332 | $1.64 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
48,996 | 2021-12-20 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.4 to $47.02 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- On December 20, 2016, the reporting person was granted an option to purchase 163,323 shares of common stock which vested in two equal installments on March 8, 2018 and March 8, 2019.